Ruxolitinib is effective in the treatment of a patient with refractory T‐ALL-Reference-Cited by-同舟云学术

Ruxolitinib is effective in the treatment of a patient with refractory T‐ALL

Published:2020-12-04 Issue:1 Volume:2 Page:139-142
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Jaramillo Sonia¹^ORCID,Hennemann Hannah¹,Horak Peter²,Teleanu Veronica²,Heilig Christoph E.²,Hutter Barbara³⁴,Stenzinger Albrecht⁵⁶,Glimm Hanno⁷⁸⁹,Goeppert Benjamin⁵,Müller‐Tidow Carsten¹,Fröhling Stefan²⁶,Schönland Stefan¹,Schlenk Richard F.¹¹⁰^ORCID

Affiliation:

1. Department of Hematology Oncology, and Rheumatology Heidelberg University Hospital University of Heidelberg Heidelberg Germany

2. Division of Translational Medical Oncology National Center for Tumor Diseases (NCT) Heidelberg, and German Cancer Research Center (DKFZ) Heidelberg Germany

3. Computational Oncology, Molecular Diagnostics Program NCT and DKFZ Heidelberg Germany

4. Division of Applied Bioinformatics DKFZ Heidelberg Germany

5. Institute of Pathology University of Heidelberg Heidelberg Germany

6. German Cancer Consortium (DKTK) Heidelberg Germany

7. Department of Translational Medical Oncology NCT Dresden, Dresden, and DKFZ Heidelberg Germany

8. Center for Personalized Oncology NCT Dresden and University Hospital Carl Gustav Carus Dresden Technical University of Dresden Dresden Germany

9. Translational Functional Cancer Genomics NCT and DKFZ Heidelberg Germany

10. NCT‐Trial Center NCT Heidelberg DKFZ and Heidelberg University Hospital Heidelberg Germany

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.143

Reference15 articles.

1. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials

2. Precision oncology based on omics data: The NCT Heidelberg experience

3. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation

4. JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 Inhibitors

5. Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87). French Group on Therapy for Adult Acute Lymphoblastic Leukemia

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions;Expert Review of Anticancer Therapy;2023-10-25

2. The JAK3^Q988P mutation reveals oncogenic potential and resistance to ruxolitinib;Molecular Carcinogenesis;2023-09-15

3. Acute Lymphoblastic Leukemia Immunotherapy Treatment: Now, Next, and Beyond;Cancers;2023-06-26

4. Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma;Annals of Hematology;2023-05-25